Search Results - "Sacco, Assuntina G"

Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma by Sacco, Assuntina G, Cohen, Ezra E

“…This review highlights the evidence-based data to support current best management practices for patients with recurrent and/or metastatic (R/M) head and neck…”
Get full text

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial by Adkins, Douglas, Prof, Ley, Jessica, BS, Neupane, Prakash, MD, Worden, Francis, Prof, Sacco, Assuntina G, MD, Palka, Kevin, MD, Grilley-Olson, Juneko E, MD, Maggiore, Ronald, MD, Salama, Noha N, PhD, Trinkaus, Kathryn, PhD, Van Tine, Brian A, MD, Steuer, Conor E, MD, Saba, Nabil F, Prof, Oppelt, Peter, MD

“…SummaryBackgroundMost head and neck squamous-cell carcinomas (HNSCCs) are driven by p16 INK4A inactivation and cyclin D1 overexpression that results in…”
Get full text

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck by Tringale, Kathryn R, Carroll, Kate T, Zakeri, Kaveh, Sacco, Assuntina G, Barnachea, Linda, Murphy, James D

“…The CheckMate 141 trial found that nivolumab improved survival for patients with recurrent or metastatic head and neck cancer (HNC). Despite the improved…”
Get full text

Adjuvant and Neoadjuvant Treatment of Skin Cancer by Sacco, Assuntina G., MD, Daniels, Gregory A., MD, PhD

“…Skin cancer represents a broad classification of malignancies, which can be further refined by histology, including basal cell carcinoma, squamous cell…”
Get full text

Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy by Vitzthum, Lucas K, Heide, Elena S, Park, Helen, Williamson, Casey W, Sheridan, Paige, Huynh-Le, Minh-Phuong, Sirak, Igor, Wei, Lichun, Tarnawski, Rafal, Mahantshetty, Umesh, Nguyen, Cammie, Mayadev, Jyoti, Yashar, Catheryn M, Sacco, Assuntina G, Mell, Loren K

“…Hematologic toxicity is a critical problem limiting treatment delivery in cancer patients undergoing concurrent chemoradiotherapy. However, the extent to which…”
Get full text

Current status of transport-disc-distraction osteogenesis for mandibular reconstruction by Sacco, Assuntina G, BS, Chepeha, Douglas B, Dr

“…Summary Surgical intervention including composite mandibulectomy is the mainstay of treatment for extrication of disease in patients with neoplasms involving…”
Get full text

Sex‐Specific Survival and Treatment Delay in Oropharyngeal Squamous Cell Carcinoma by Kalavacherla, Sandhya, Poulhazan, Solene, Funk, Emily, Sacco, Assuntina G., Guo, Theresa

“…Objective As the majority of oropharyngeal squamous cell carcinoma (OPSCC) is diagnosed in males, outcomes among females are not well‐characterized. We…”
Get full text

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial by Sacco, Assuntina G, Chen, Ruifeng, Worden, Francis P, Wong, Deborah J L, Adkins, Douglas, Swiecicki, Paul, Chai-Ho, Wanxing, Oppelt, Peter, Ghosh, Debanjali, Bykowski, Julie, Molinolo, Alfredo, Pittman, Emily, Estrada, M Valeria, Gold, Kathryn, Daniels, Gregory, Lippman, Scott M, Natsuhara, Amanda, Messer, Karen, Cohen, Ezra E W

“…Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are active as single agents and in combination with cytotoxic chemotherapy for recurrent or…”
Get full text

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy by Khagi, Yulian, Goodman, Aaron M, Daniels, Gregory A, Patel, Sandip P, Sacco, Assuntina G, Randall, James M, Bazhenova, Lyudmila A, Kurzrock, Razelle

“…Tumor mutational burden detected by tissue next-generation sequencing (NGS) correlates with checkpoint inhibitor response. However, tissue biopsy may be costly…”
Get full text

Inevitable Progress-Relying on the Immune System, Not Chance by Sacco, Assuntina G, Cohen, Ezra E W

“…Locoregional recurrence of head and neck cancer after curative therapy portends a poor prognosis even when resectable. Immunotherapy has opened the door to…”
Get full text

Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors by Sacco, Assuntina G, Worden, Francis P

“…The majority of patients with head and neck squamous cell carcinoma (HNSCC) present with locally advanced disease, which requires site-specific combinations of…”
Get full text

Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society Appropriate Use Criteria by Ward, Matthew C., Koyfman, Shlomo A., Bakst, Richard L., Margalit, Danielle N., Beadle, Beth M., Beitler, Jonathan J., Chang, Steven Shih-Wei, Cooper, Jay S., Galloway, Thomas J., Ridge, John A., Robbins, Jared R., Sacco, Assuntina G., Tsai, C. Jillian, Yom, Sue S., Siddiqui, Farzan

Get full text

Interdisciplinary Approach to Expedited Outpatient Gastrostomy Tube Placement in Head and Neck Cancer Patients: A Single Center Retrospective Study by Haldeman, Pearce B., Ghani, Mansur A., Rubio, Patricia, Pineda, Minette, Califano, Joseph, Sacco, Assuntina G., Minocha, Jeet, Berman, Zachary T.

“…Treatment for head and neck cancer (HNC) can lead to decreased oral intake which often requires gastrostomy tube (g-tube) placement to provide nutritional…”
Get full text

Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic by Chaves, Aline Lauda Freitas, Castro, Ana Ferreira, Marta, Gustavo Nader, Junior, Gilberto Castro, Ferris, Robert L., Giglio, Raúl Eduardo, Golusinski, Wojciech, Gorphe, Philippe, Hosal, Sefik, Leemans, C. René, Magné, Nicolas, Mehanna, Hisham, Mesía, Ricard, Netto, Eduardo, Psyrri, Amanda, Sacco, Assuntina G., Shah, Jatin, Simon, Christian, Vermorken, Jan B., Kowalski, Luiz Paulo

Get full text

A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma by Dennis, Michael J., Sacco, Assuntina G., Qi, Yuchen, Bykowski, Julie, Pittman, Emily, Chen, Ruifeng, Messer, Karen, Cohen, Ezra E.W., Gold, Kathryn A.

“…•Palbociclib, avelumab, and cetuximab was well tolerated in R/M HNSCC.•No unexpected toxicities were observed.•Promising response rates were seen (ORR 42%) We…”
Get full text

Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer by Acevedo, Joseph R, Fero, Katherine E, Wilson, Bayard, Sacco, Assuntina G, Mell, Loren K, Coffey, Charles S, Murphy, James D

“…Purpose Recently, a large randomized trial found a survival advantage among patients who received elective neck dissection in conjunction with primary surgery…”
Get full text

Sister partnership to overcome the global burden of cancer by Magné, Nicolas, Sotton, Sandrine, Varges Gomes, Ana, Marta, Gustavo Nader, Giglio, Raúl Eduardo, Mesía, Ricard, Psyrri, Amanda, Sacco, Assuntina G, Shah, Jatin, Diao, Peng, Malekzadeh Moghani, Mona, Moreno-Acosta, Pablo, Bouleftour, Wafa, Deutsch, Eric

“…Emerging countries are currently facing an increasing burden of cancer while they do not have adequate prevention, monitoring and research capabilities to…”
Get full text

Serum antibodies open the door to prediction and prognostication in human papillomavirus–related head and neck cancer by Sacco, Assuntina G., Cohen, Ezra E.

“…In human papillomavirus–related head and neck cancer, who can be de‐escalated, and who requires more intensive therapy to achieve similar oncologic efficacy?…”
Get full text

Redefining Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer Based on Relative Risk by Morse, Ryan T., Nelson, Tyler J., Liu, Hannah C., Sangchan, Prangrawee, Chitti, Bhargava, Thompson, Caroline A., Henderson, Gerald, Williamson, Casey W., Todd, Jake R., Prajapati, Divya P., Vitzthum, Lucas K., Sharabi, Andrew B., Zou, Jingjing, Sacco, Assuntina G., Coffey, Charley S., Sanghvi, Parag, Rahn, Douglas A., Lominska, Christopher E., Shen, Colette J., Chera, Bhishamjit S., Mell, Loren K.

“…Randomized trials have found that patients with locoregionally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC) do not benefit from treatment…”
Get full text

Quality improvement intervention to reduce time to postoperative radiation in head and neck free flap patients by Voora, Rohith S., Stramiello, Joshua A., Sumner, Whitney A., Finegersh, Andrey, Mohammadzadeh, Amir, Fouania, John, Ramsey, Celia, Blumenfeld, Liza, Sacco, Assuntina G., Mell, Loren K., Califano, Joseph A., Orosco, Ryan K.

“…Background Best‐practice guidelines for head and neck cancer patients advise postoperative radiation therapy (PORT) initiation within 6 weeks of surgery. We…”
Get full text